clinical trial · NCT05684380
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
EMS·phase3·unknown·n = 514
Allergic RhinitisMAZ-101associationDYMISTA®
brief summary
The purpose of this study is to evaluate the efficacy and safety of MAZ-101 in the treatment of moderate-severe persistent allergic rhinitis.
started
Sep 1, 2024
primary completion
Nov 1, 2024
completion
May 1, 2025
last updated
Feb 16, 2024
official title
National, Multicenter, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol